CY1116970T1 - Fkbp-l και χρησεις αυτων ως αναστολεις αγγειογενεσης - Google Patents

Fkbp-l και χρησεις αυτων ως αναστολεις αγγειογενεσης

Info

Publication number
CY1116970T1
CY1116970T1 CY20151101070T CY151101070T CY1116970T1 CY 1116970 T1 CY1116970 T1 CY 1116970T1 CY 20151101070 T CY20151101070 T CY 20151101070T CY 151101070 T CY151101070 T CY 151101070T CY 1116970 T1 CY1116970 T1 CY 1116970T1
Authority
CY
Cyprus
Prior art keywords
fkbp
vascular
antibodies
polypeptides
angiogenesis
Prior art date
Application number
CY20151101070T
Other languages
Greek (el)
English (en)
Inventor
Tracy Robson
Andrea Valentine
Martin O'rourke
David Hirst
Original Assignee
Almac Discovery Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Limited filed Critical Almac Discovery Limited
Publication of CY1116970T1 publication Critical patent/CY1116970T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
CY20151101070T 2006-06-09 2015-11-26 Fkbp-l και χρησεις αυτων ως αναστολεις αγγειογενεσης CY1116970T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0611405.2A GB0611405D0 (en) 2006-06-09 2006-06-09 FKBP-L: A novel inhibitor of angiogenesis
EP07733118.9A EP2040728B1 (en) 2006-06-09 2007-06-08 Fkbp-l and uses thereof as inhibitors of angiogenesis

Publications (1)

Publication Number Publication Date
CY1116970T1 true CY1116970T1 (el) 2017-04-05

Family

ID=36745574

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151101070T CY1116970T1 (el) 2006-06-09 2015-11-26 Fkbp-l και χρησεις αυτων ως αναστολεις αγγειογενεσης

Country Status (18)

Country Link
US (3) US9381228B2 (cg-RX-API-DMAC7.html)
EP (1) EP2040728B1 (cg-RX-API-DMAC7.html)
JP (1) JP5474535B2 (cg-RX-API-DMAC7.html)
CN (1) CN101489575B (cg-RX-API-DMAC7.html)
AU (1) AU2007255196B2 (cg-RX-API-DMAC7.html)
CA (1) CA2657947C (cg-RX-API-DMAC7.html)
CY (1) CY1116970T1 (cg-RX-API-DMAC7.html)
DK (1) DK2040728T3 (cg-RX-API-DMAC7.html)
ES (1) ES2548332T3 (cg-RX-API-DMAC7.html)
GB (1) GB0611405D0 (cg-RX-API-DMAC7.html)
HU (1) HUE028099T2 (cg-RX-API-DMAC7.html)
IL (1) IL195580A (cg-RX-API-DMAC7.html)
NZ (2) NZ600690A (cg-RX-API-DMAC7.html)
PL (1) PL2040728T3 (cg-RX-API-DMAC7.html)
PT (1) PT2040728E (cg-RX-API-DMAC7.html)
SI (1) SI2040728T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007141533A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200810323B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
WO2005044839A2 (en) 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
GB0724393D0 (en) * 2007-12-14 2008-01-23 Univ Ulster Use of FKBPL gene to identify a cause of infertility
US20110144306A1 (en) 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
WO2010034032A2 (en) 2008-09-22 2010-03-25 Aileron Therapeutic, Inc. Methods for preparing purified polypeptide compositions
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
GB0908589D0 (en) * 2009-05-19 2009-06-24 Univ Belfast Assay method
CA2768299C (en) * 2009-07-13 2018-03-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
AU2010298338A1 (en) 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2012021875A1 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with triazole linkers
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
WO2013052803A2 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
SMT202100337T1 (it) 2012-09-26 2021-07-12 Harvard College Peptidi graffati bloccati con prolina e loro usi
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
JP6568515B2 (ja) 2013-03-13 2019-08-28 プレジデント アンド フェローズ オブ ハーバード カレッジ ステープルドおよびステッチドポリペプチドならびにその使用
CN105492460A (zh) 2013-06-14 2016-04-13 哈佛大学的校长及成员们 稳定化多肽胰岛素受体调控剂
EP3145523A4 (en) 2014-05-21 2018-02-21 President and Fellows of Harvard College Ras inhibitory peptides and uses thereof
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
DK3402480T3 (da) 2016-01-11 2021-06-28 Epicentrx Inc Sammensætninger og fremgangsmåder til intravenøs administration af 2-brom-1-(3,3-dinitroazetidin-1-yl)ethanon
WO2017136312A1 (en) 2016-02-02 2017-08-10 Splash Pharmaceuticals, Inc. Combination therapy with a6, chemotherapeutic agents, radiation therapy, or a combination thereof for the treatment of cancer
WO2017221011A1 (en) * 2016-06-22 2017-12-28 Almac Discovery Limited Treatment of ocular disease
AU2017342436C1 (en) 2016-10-14 2022-11-03 Epicentrx, Inc. Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
US11376308B2 (en) 2016-10-19 2022-07-05 Royal College Of Surgeons In Ireland Use of FKBP-L polypeptides and nucleic acids for the treatment of obesity
CN108362870A (zh) * 2017-01-27 2018-08-03 武汉三鹰生物技术有限公司 一种用于人fkbpl蛋白的酶联免疫检测及制备方法
US11744859B2 (en) 2017-07-07 2023-09-05 Epicentrx, Inc. Compositions and methods for parenteral administration of therapeutic agents
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
CN111603567B (zh) 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
CN113702632A (zh) * 2021-09-02 2021-11-26 深圳市光与生物科技有限公司 一种快速检测子痫前期的免疫层析检测卡及其制备方法与应用
CN114702564A (zh) * 2021-12-15 2022-07-05 江苏省人民医院（南京医科大学第一附属医院） 一种外泌体肽及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3194732A (en) 1960-10-03 1965-07-13 Neuhauser Irene Assisting healing of skin-denuded areas on the body with dried non-fibrous egg-shellmembrane products and compositions therefor
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
JPS60501277A (ja) 1983-05-09 1985-08-08 ザ　ゼネラル　エレクトリツク　カンパニ−，ピ−．エル．シ− 陰極線管表示装置
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
JP3065628B2 (ja) * 1988-12-19 2000-07-17 三井化学株式会社 ヒト免疫グロブリン遺伝子関連ｄｎａ断片及び該ｄｎａ断片を用いる診断方法
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
AU648140B2 (en) * 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
AU681405B2 (en) * 1993-06-29 1997-08-28 Chiron Corporation A truncated keratinocyte growth factor (KGF) having increased biological activity
JPH11513405A (ja) * 1995-10-11 1999-11-16 カイロン コーポレイション 創傷治癒のためのｐｄｇｆ、ｋｇｆ、ｉｇｆ、およびｉｇｆｂｐの配合物
EP0980432A1 (en) 1997-05-01 2000-02-23 Amgen, Inc. Chimeric opg polypeptides
US6583168B1 (en) 1997-11-25 2003-06-24 Applera Corporation Sulfonated diarylrhodamine dyes
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
WO1999065939A1 (en) * 1998-06-18 1999-12-23 Curagen Corporation INTERACTION OF p27(KIP1) WITH FKBP-12
WO2000021992A1 (en) * 1998-10-09 2000-04-20 Shanghai Second Medical University A human fk506 binding protein (fkbp)
EP1088857A4 (en) 1999-04-13 2005-01-19 Hayashibara Biochem Lab CYANINE COLOR
EP1210046A4 (en) * 1999-06-22 2007-05-02 Res Dev Foundation IMPROVED DRESSING THAT CAN ACCELERATE THE HEALING OF INJURIES
CA2378116A1 (en) * 1999-07-06 2001-01-11 Incyte Genomics, Inc. Human immune response molecules
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20030125246A9 (en) * 2000-01-31 2003-07-03 Rosen Craig A. Nucleic acids, proteins, and antibodies
NZ526708A (en) * 2000-11-28 2005-07-29 Wyeth Corp Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU2002255478A1 (en) * 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7244819B2 (en) 2001-06-22 2007-07-17 Roche Diagnostics Operations, Inc. Fusion polypeptides, vaccines and compositions of FKBP chaperones and target polypeptides
US6856185B2 (en) * 2001-10-23 2005-02-15 Arris International, Inc. Simple RMS to DC converter
US20040053388A1 (en) * 2002-01-03 2004-03-18 Eckert Jorg H. Detection of protein conformation using a split ubiquitin reporter system
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
EP2040728B1 (en) 2015-09-02
PT2040728E (pt) 2015-10-29
IL195580A0 (en) 2011-08-01
WO2007141533A2 (en) 2007-12-13
ES2548332T3 (es) 2015-10-15
US20160340401A1 (en) 2016-11-24
CA2657947C (en) 2017-11-21
ZA200810323B (en) 2013-05-29
NZ600690A (en) 2014-03-28
SI2040728T1 (sl) 2015-12-31
JP5474535B2 (ja) 2014-04-16
DK2040728T3 (en) 2015-10-26
WO2007141533A3 (en) 2008-07-31
US10577406B2 (en) 2020-03-03
CN101489575A (zh) 2009-07-22
EP2040728A2 (en) 2009-04-01
GB0611405D0 (en) 2006-07-19
AU2007255196B2 (en) 2013-10-03
JP2009539367A (ja) 2009-11-19
IL195580A (en) 2013-07-31
US9381228B2 (en) 2016-07-05
US20090192085A1 (en) 2009-07-30
PL2040728T3 (pl) 2016-02-29
CA2657947A1 (en) 2007-12-13
CN101489575B (zh) 2013-08-28
AU2007255196A1 (en) 2007-12-13
NZ573425A (en) 2012-07-27
US20160340402A1 (en) 2016-11-24
HUE028099T2 (en) 2016-11-28

Similar Documents

Publication Publication Date Title
CY1116970T1 (el) Fkbp-l και χρησεις αυτων ως αναστολεις αγγειογενεσης
SA520420658B1 (ar) جزيئات ربط ضد bcma واستخداماتها
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
EA202091540A1 (ru) Антитела к lilrb2
CY1124272T1 (el) Κατασκευασματα παραλλαγης sirp-αλφα και χρησεις αυτων
MX2019014318A (es) Proteinas de union a nectina-4 y metodos de uso de las mismas.
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
HUS1300076I1 (hu) Diaril-hidantoin vegyületek
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
EA201891366A1 (ru) Гуманизированные антитела против cd73
MX375439B (es) Moleculas de union cd37 y sus inmunoconjugados.
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
AR105444A1 (es) Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
GB2532619A (en) Sirp-Alpha Variant Constructs And Uses Thereof
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
BR112015021838A2 (pt) amatoxina, método de síntese, composição farmacêutica
TN2016000472A1 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer.
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
EA200901249A1 (ru) Ингибиторы связывания протеинкиназ